RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Nashville, TN · +21 more sites
Prostate Cancer clinical trials in Nashville, TN
33 recruiting prostate cancer studies with a site in Nashville, TN.
RecruitingPhase 3NCT07365995
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Sponsor: BioNTech SE
Nashville, TN · +19 more sites
RecruitingPhase 1NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Sponsor: Pfizer
Nashville, TN · +43 more sites
RecruitingPhase 1NCT07824349
JUR-003 in Adult Patients With Metastatic Prostate Cancer
Sponsor: Juri Biosciences, Inc.
Nashville, TN · +3 more sites
RecruitingPhase 3NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Sponsor: Pfizer
Chattanooga, TN · +124 more sites
RecruitingPhase 2NCT07745361
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Sponsor: Monte Rosa Therapeutics, Inc
Nashville, TN · +13 more sites
RecruitingPhase 1 / Phase 2NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Sponsor: Parabilis Medicines, Inc.
Nashville, TN · +29 more sites
RecruitingPhase 3NCT07723248
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Sponsor: ORIC Pharmaceuticals
Nashville, TN · +10 more sites
RecruitingPhase 2NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Sponsor: Daiichi Sankyo
Nashville, TN · +12 more sites
RecruitingPhase 1NCT06095089
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Nashville, TN · +11 more sites
RecruitingPhase 1 / Phase 2NCT06800313
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Nashville, TN · +15 more sites
RecruitingPhase not listedNCT07124000
DESTINY-PANTUMOUR04
Sponsor: AstraZeneca
Nashville, TN · +17 more sites
RecruitingPhase 1NCT07277270
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Sponsor: GlaxoSmithKline
Nashville, TN · +4 more sites
RecruitingPhase 2NCT05489211
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Sponsor: AstraZeneca
Nashville, TN · +16 more sites
RecruitingPhase 3NCT07213674
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Sponsor: Amgen
Nashville, TN · +43 more sites
RecruitingPhase 1NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Sponsor: SystImmune Inc.
Nashville, TN · +21 more sites
RecruitingPhase 2NCT05011383
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Sponsor: VA Office of Research and Development
Memphis, TN · Nashville, TN · +15 more sites
RecruitingPhase 1NCT07493512
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Sponsor: Amgen
Nashville, TN · +11 more sites
RecruitingPhase 3NCT06056830
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Sponsor: Clarity Pharmaceuticals Ltd
Nashville, TN · +28 more sites
RecruitingPhase 1NCT06440005
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Sponsor: Angiex, Inc.
Nashville, TN · +6 more sites
RecruitingPhase 1NCT07545811
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Janux Therapeutics
Nashville, TN · +5 more sites
RecruitingPhase 1NCT04221542
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Amgen
Nashville, TN · +24 more sites
RecruitingPhase 1NCT06966024
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Sponsor: Deciphera Pharmaceuticals, LLC
Nashville, TN · +7 more sites
RecruitingPhase 2NCT06842498
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor: Kyntra Bio
Nashville, TN · +22 more sites
RecruitingPhase 1NCT06545942
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Sponsor: MOMA Therapeutics
Nashville, TN · +11 more sites
RecruitingPhase 3NCT07052214
PSMA PET Combined With MRI for the Detection of PCa
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Germantown, TN · Nashville, TN · +14 more sites
RecruitingPhase 3NCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Sponsor: Canadian Cancer Trials Group
Nashville, TN · +373 more sites
RecruitingPhase 2NCT04606446
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Sponsor: Pfizer
Nashville, TN · +22 more sites
RecruitingPhase 1 / Phase 2NCT05785741
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
Nashville, TN · +14 more sites
RecruitingPhase 1NCT07181473
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Sponsor: Phrontline Biopharma
Nashville, TN · +2 more sites
RecruitingPhase 1 / Phase 2NCT05914116
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
Nashville, TN · +27 more sites
RecruitingPhase 2NCT06134232
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Sponsor: Dendreon
Nashville, TN · +30 more sites
RecruitingPhase 1 / Phase 2NCT04503265
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Sponsor: AtlasMedx, Incorporated
Nashville, TN · +3 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.